drugset / Trial / NCT04994106

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

NCT04994106

Phase 1 Completed 98 enrolled AstraZeneca
RandomizedSequentialTriple-blindOther

Summary

This study will assess the safety, tolerability, and pharmacokinetic (PK) of AZD5462 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy male and female participants and healthy participants of Japanese descent.

Timeline

Start
2021-07-27
Primary completion
2022-09-20
Completion
2022-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5462 Unknown

Indications

No indication recorded.